Association between dipeptidyl peptidase-4 inhibitors and glucagon-like peptide-1 receptor agonists and COVID-19 infection and adverse outcomes: a cohort study
Thompson W, Yu B, Porter J, Fang J, Ferreira-Legere LE, Austin PC, Jackevicius CA, Ross H, Lee DS, Weisman A, Farkouh ME, Gershon AS, Atzema CL, Kwong JC, Ha A, Džavík V, Udell JA. BMJ Open Diabetes Res Care. 2025; 13(4):e004677.